Header graphic for print
Dangerous Drugs & Medical Devices News & Commentary on Prescription Drug & Medical Device Lawsuits

Monthly Archives: May 2014

2012 – About 30% of infants exposed to SSRIs in utero exhibit neonatal withdrawal symptoms

Posted in SSRI Birth Defects

A 2012 article by V. Bellissima et al. published in Current Medicinal Chemistry titled “selective serotonin reuptake inhibitor drugs (SSRIs) during pregnancy” cites stark data regarding perinatal outcomes of children born to mothers who used SSRI during pregnancy. This team, from a children’s hospital in Italy, states that “Although a number of studies have shown… Continue Reading

2012 – 40% of metal-on-metal hip replacement patients face adverse reaction to metal debris

Posted in DePuy Hip Replacement

A 2012 article by I.A. Malek et al. published in Journal of Bone and Joint Surgery titled “The sensitivity, specificity and predictive values of raised plasma metal ion levels in the diagnosis of adverse reaction to metal debris in symptomatic patients with a metal-on-metal arthroplasty of the hip.” helps demonstrate the rate at which patients… Continue Reading

2012 – Paxil linked to increased rate for heart defects

Posted in Paxil Birth Defects, SSRI Birth Defects

In 2012, more research connected Paxil (paroxetine) to increased rates of cardiac malformations – that is, birth defects of the heart.  In this study, titled “Paroxetine use during pregnancy and perinatal outcomes including types of cardiac malformations in Quebec and France: a short communication.” by A. Bérard et al. in that year’s July edition of… Continue Reading

2012 – Lexapro associated with perinatal complications

Posted in SSRI Birth Defects

Though the article does not detail which perinatal complications have been linked to Lexapro (escitalopram), a piece by C. Bellantuono et al. published in the November, 2012 edition of Human Psychopharmacology drew that link. Lexapro is a selective serotonin reuptake inhibitor (SSRI).  This drug and drugs like it work to regulate levels of serotonin in… Continue Reading

2013 – Hypospadias linked to Effexor in pregnancy

Posted in Effexor Birth Defects, SSRI Birth Defects

A 2013 article by J.N. Lind et al. published in Pharmacoepidemiology and Drug Safety titled “Maternal medication and herbal use and risk for hypospadias: data from the National Birth Defects Prevention Study, 1997-2007.” made links between Effexor and birth defects, and between Clomid and birth defects. Using “data from the National Birth Defects Prevention Study,… Continue Reading

2014 – Risk for PPHN increased by 250% with SSRI use in pregnancy

Posted in SSRI Birth Defects

A study published in the January, 2014 edition of British Medical Journal titled “Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis.” by S. Grigoriadis et al. provides further insight into the relationship between SSRI use during pregnancy and persistent pulmonary hypertension of the newborn (PPHN). Reviewing seven previously-conducted… Continue Reading

2010 – Canadian study shows Paxil, Effexor raise risk for spontaneous abortion

Posted in Effexor Birth Defects, Paxil Birth Defects, SSRI Birth Defects

In 2010, an article published in Canadian Medical Association Journal titled “Use of antidepressants during pregnancy and the risk of spontaneous abortion.” illustrated the link between SSRI use during pregnancy and increased risk for spontaneous abortion. This study, led by H.R. Nakhai-Pour of The University of Montreal, “obtained data from the Quebec Pregnancy Registry for… Continue Reading

2010 – Many studies demonstrate the risks of SSRI use in pregnancy

Posted in SSRI Birth Defects

An article published in 2010 by A. Udechuku et al. titled “Antidepressants in pregnancy: a systematic review.” further demonstrates the dangers of SSRI use in pregnancy. A meta-analysis, this study reviewed previously conducted studies published in the literature and looked to see if there was a trend in data.  The team writes that with respect… Continue Reading

2012 – SSRI use during pregnancy doubles risk for preterm birth

Posted in SSRI Birth Defects

In 2012, H. El Marroun et al published a study titled “Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes.” in Archives of General Psychiatry.  This further demonstrates the breadth of knowledge in the medical community regarding the connection between selective serotonin reuptake inhibitor (SSRI) drugs and adverse birth… Continue Reading

2010 – Paxil, Effexor dramatically raise risk for spontaneous abortion

Posted in Effexor Birth Defects, Paxil Birth Defects, SSRI Birth Defects

A recent article by P. Broy et al. published in Current Drug Delivery titled “Gestational exposure to antidepressants and the risk of spontaneous abortion: a review.” provides important insight into the connection between in vitro exposure to SSRI drugs and spontaneous abortion.  SSRI drugs are a relatively new class of antidepressant medications, which aim to… Continue Reading

2014 – Research shows nearly 3-fold increased risk for ejaculation disorder with finasteride (Propecia, Proscar)

Posted in Propecia / Proscar

An article published in the April, 2014 edition of Journal of Sexual Medicine by M. Gacci et al. titled “Impact of Medical Treatments for Male Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia on Ejaculatory Function: A Systematic Review and Meta-Analysis.” provides additional support for finasteride’s link to sexual dysfunction.  Finasteride is the active… Continue Reading

2014 – Study shows 54% increased risk for cardiovascular side effects with AndroGel

Posted in Androgel

According to a recent article published in Current Opinion in Endocrinology, Diabetes, and Obesity by CM Schooling titled “Testosterone and cardiovascular disease.”,  there is a clear link between use of testosterone supplements such as AndroGel and increased risk for heart attack. Schooling (2014) writes, “Use of testosterone among men is increasing rapidly. Low serum testosterone… Continue Reading

2005 – More evidence for the Proscar-sexual side effects link

Posted in Propecia / Proscar

In 2005, an article titled “Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).” appearing in the medical journal European Urology, provided further evidence of scholarly knowledge of the link between finasteride and sexual dysfunction long before warning labels for the drug were updated. Finasteride is the active chemical in… Continue Reading

2005 – Finasteride “clearly associated with sexual side effects”

Posted in Propecia / Proscar

An article published in a 2005 edition of Comprehensive Therapy titled “Noninvasive management of lower urinary tract symptoms and sexual dysfunction associated with benign prostatic hyperplasia in the primary care setting.” makes an important note of the connection between finasteride and sexual side effects.  Finasteride is the active chemical in Proscar, a drug commonly used… Continue Reading

2008 study cites link between finasteride and sexual side effects

Posted in Propecia / Proscar

Finasteride is a chemical in a larger class called 5alpha-reductase inhibitors, and is the active chemical in the hair loss drug Propecia (finasteride 1mg), and the benign prostatic hyperplasia drug Proscar (finasteride 5mg).  Recently, a number of scientific studies have demonstrated that finasteride use is linked to adverse sexual effects including erectile dysfunction, ejaculation disorder,… Continue Reading

2010 – Propecia doubles risk for erectile dysfunction

Posted in Propecia / Proscar

A 2010 article published in Archives of Dermatology by JM Mella et al. titled “Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review.” further demonstrates that finasteride use is linked to sexual side effects.  Finasteride is the active chemical in Alopecia, the BPH drug Proscar, the hair loss drug Propecia, among others…. Continue Reading

2012 – JAMA: “Prostate, Baldness Drugs Linked to Sexual Dysfunction”

Posted in Propecia / Proscar

An article published in the May, 2012 edition of Journal of the American Medical Association titled “Prostate, Baldness Drugs Linked to Sexual Dysfunction” provides important insight into the link that Proscar (finasteride 5mg, used to treat BPH) and Propecia (finasteride 1mg, used to treat male pattern hair loss) have with a range of adverse sexual… Continue Reading

April 2012 – FDA Requires PROPECIA and PROSCAR Warning Label Update

Posted in Propecia / Proscar

Here is an excerpt from the FDA’s frequently-asked questions page for required the Proscar and Propecia Warning Label Update: Questions and Answers: Finasteride Label Changes “On April 11, 2012, the U.S. Food and Drug Administration (FDA) announced changes to the professional labels for Propecia (finasteride 1 mg) and Proscar (finasteride 5 mg) to expand the… Continue Reading

2012 – Propecia, Proscar linked to sexual side effects

Posted in Propecia / Proscar

In a 2012 edition of International Journal of Clinical Practice, an article by SA Kaplan et al. titled “A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.” gave important insight into… Continue Reading

2007 – Study shows rate for Proscar side effects higher than warning label

Posted in Propecia / Proscar

In 2007, five years before Proscar and Propecia warning labels were required to be updated by the FDA to include information on sexual side effects, an important paper was published in Clinical Therapeutics by MJ Naslund titled “A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.”. This study reviewed… Continue Reading

Tricky language in company-funded Proscar study

Posted in Propecia / Proscar

Just a quick note about a finasteride study I recently read in Archives of Internal Medicine.  For clarity, finasteride is the active chemical in the hair loss drug Propecia and the benign prostatic hyperplasia (BPH) drug Proscar, and both Propecia and Proscar are manufactured by Merck & Co., Inc. This study, titled “Maintenance of clinical… Continue Reading

1996 – Study links finasteride and sexual side effects long before warning labels updated

Posted in Propecia / Proscar

Though the warning labels for Propecia (finasteride 1mg) and Proscar (finasteride 5mg) were not updated to include information about long-term sexual side effects until April, 2012, research has been available to the public for over a decade that shows finasteride is connected with such adverse effects.  Here, we discuss an article appearing in the November,… Continue Reading

1999 – Finasteride linked to adverse sexual effects

Posted in Propecia / Proscar

An article from the October, 1999 edition of Urology went great lengths to provide important insight into the connection between finasteride (the active chemical in Propecia, Proscar, and other drugs) and sexual side-effects.  This article is titled “Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS… Continue Reading

2010 – Finasteride linked to range of sexual side-effects

Posted in Propecia / Proscar

In 2010, an article appearing in the October edition of medical journal The Cochrane Database of Systematic Reviews titled “Finasteride for benign prostatic hyperplasia.” helps us further understand the connection between use of finasteride (the active chemical in benign prostatic hyperplasia drug Proscar) and adverse sexual side effects. This research team, led by J. Tacklind,… Continue Reading